| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACE |
| Uniprot No | P12821 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1306aa |
| 氨基酸序列 | MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLLKYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTSQVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRIIKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKYEDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLERLFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPSAPSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHASAWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGDVLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGSITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHEALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSYFKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQWLLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS |
| 预测分子量 | 71 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACE(血管紧张素转换酶)重组蛋白研究的3篇参考文献示例(注：以下为虚构示例，仅作格式参考)：
---
1. **文献名称**：*"High-Yield Expression and Purification of Recombinant Human ACE in Mammalian Cell Systems"*
**作者**：Zhang, L. et al.
**摘要**：本研究报道了在哺乳动物细胞(HEK293)中高效表达人源ACE重组蛋白的方法，通过优化载体设计和培养条件，获得高纯度且具有酶活性的蛋白，适用于药物筛选和结构研究。
---
2. **文献名称**：*"Functional Characterization of a Novel ACE Isoform Expressed in Drosophila S2 Cells"*
**作者**：Martinez, R. & Kumar, S.
**摘要**：利用果蝇S2昆虫细胞系统成功表达新型ACE重组蛋白变体，并验证其催化血管紧张素I转化的活性，为研究ACE的进化多样性提供新模型。
---
3. **文献名称**：*"Engineering Thermostable ACE Mutants for Enhanced Industrial Applications"*
**作者**：Tanaka, H. et al.
**摘要**：通过定向进化技术改造ACE重组蛋白，获得耐高温突变体，显著提升其在食品加工和生物催化中的稳定性，并解析关键氨基酸位点的作用机制。
---
**提示**：如需真实文献，建议在PubMed或Google Scholar中搜索关键词：
`"recombinant angiotensin-converting enzyme" expression` 或 `"ACE recombinant protein" structural/functional`，筛选近五年高被引论文。
**Background of Recombinant ACE Protein**
Angiotensin-converting enzyme (ACE), a key zinc metalloprotease, plays a central role in regulating blood pressure and fluid balance by converting angiotensin I to the vasoconstrictor angiotensin II and degrading bradykinin. First isolated in the 1950s, ACE became a major therapeutic target for hypertension and cardiovascular diseases, leading to the development of ACE inhibitors like captopril.
Recombinant ACE protein is produced using genetic engineering techniques, where the ACE gene is cloned into expression systems (e.g., mammalian cells, bacteria, or yeast) to enable large-scale, high-purity production. This approach overcomes limitations of isolating ACE from natural sources, such as low yield and contamination risks. Recombinant ACE retains enzymatic activity and structural features, including its two homologous catalytic domains (N- and C-terminal), critical for substrate processing.
Research on recombinant ACE has expanded beyond cardiovascular biology. It serves as a tool to study ACE’s role in metabolic disorders, inflammation, and fibrosis. Additionally, ACE2. a homolog discovered in 2000. gained prominence as the receptor for SARS-CoV-2. spurring renewed interest in recombinant ACE/ACE2 proteins for COVID-19 research and therapeutic development.
Pharmaceutical applications include drug screening, antibody production, and structure-function studies to design next-generation inhibitors. Recombinant ACE also aids in diagnostic assay development and biomarker research. Its versatility and scalability make it indispensable for both basic science and translational medicine, highlighting its enduring significance in biomedical innovation.
×
